Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 11

Imetelstat and IMerge Trial Review

,

Panelists discuss how imetelstat, a telomerase inhibitor recently approved by the FDA on June 6, 2024, works and its efficacy as demonstrated in the IMerge trial, while highlighting key adverse events that community oncologists should be vigilant about when considering this treatment for patients with lower-risk MDS.

EP. 1: Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment
EP. 2: Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying
EP. 3: Clinical Scenario 1: 76-Year-Old Man With Newly Diagnosed MDS With Symptomatic Anemia, RS Positive
EP. 4: Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes
EP. 5: First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting
EP. 6: Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring
EP. 7: Second-Line LR- MDS Setting: Treatment Options and Considerations
EP. 8: Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative
EP. 9: Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels
EP. 10: First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient
Now Viewing
EP. 11: Imetelstat and IMerge Trial Review
EP. 12: Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies
EP. 13: The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs

Video content above is prompted by the following:

  • Please review imetelstat, including mechanism of action and FDA approval (imetelstat, June 6, 2024).
  • IMerge trial (Platzbecker U, et al. Lancet. 2024;403(10423):249-260.)
  • What are some key adverse events community oncologists should be aware of with imetelstat?

Related Content:

Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical PracticeClinicalInsightsVideo Series
Single-Agent Immune Therapy in UC: The Need for More
Outlining the Current First-Line Treatment Landscape in Metastatic Urothelial Cancer: Starting With a Cisplatin-Ineligible Patient Case
Emerging role of doublet triplet therapies in R/R CLL: Expert Perspectives